Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective
- PMID: 18285443
- DOI: 10.1177/0962280207081851
Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective
Abstract
The last two decades have seen a lot of development in the area of surrogate marker validation. One of these approaches places the evaluation in a meta-analytic framework, leading to definitions in terms of trial- and individual-level association. A drawback of this methodology is that different settings have led to different measures at the individual level. Using information theory, Alonso et al. proposed a unified framework, leading to a new definition of surrogacy, which offers interpretational advantages and is applicable in a wide range of situations. In this work, we illustrate how this information-theoretic approach can be used to evaluate surrogacy when both endpoints are of a time-to-event type. Two meta-analyses, in early and advanced colon cancer, respectively, are then used to evaluate the performance of time to cancer recurrence as a surrogate for overall survival.
Similar articles
-
Surrogate marker evaluation from an information theory perspective.Biometrics. 2007 Mar;63(1):180-6. doi: 10.1111/j.1541-0420.2006.00634.x. Biometrics. 2007. PMID: 17447943
-
A unifying approach for surrogate marker validation based on Prentice's criteria.Stat Med. 2006 Jan 30;25(2):205-21. doi: 10.1002/sim.2315. Stat Med. 2006. PMID: 16220497
-
Alternative methods to evaluate trial level surrogacy.Clin Trials. 2008;5(3):194-208. doi: 10.1177/1740774508091677. Clin Trials. 2008. PMID: 18559408
-
Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints.Clin Trials. 2007;4(6):587-97. doi: 10.1177/1740774507084979. Clin Trials. 2007. PMID: 18042568 Review.
-
Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.Cancer J. 2009 Sep-Oct;15(5):421-5. doi: 10.1097/PPO.0b013e3181b9c602. Cancer J. 2009. PMID: 19826362 Review.
Cited by
-
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.Int J Clin Oncol. 2009 Apr;14(2):102-11. doi: 10.1007/s10147-009-0885-4. Epub 2009 Apr 24. Int J Clin Oncol. 2009. PMID: 19390940 Review.
-
Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.Biostatistics. 2011 Jul;12(3):478-92. doi: 10.1093/biostatistics/kxq082. Epub 2011 Jan 20. Biostatistics. 2011. PMID: 21252079 Free PMC article.
-
Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments.Pharm Stat. 2022 Jul;21(4):740-756. doi: 10.1002/pst.2219. Pharm Stat. 2022. PMID: 35819121 Free PMC article. Review.
-
Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model.Biometrics. 2015 Jun;71(2):460-8. doi: 10.1111/biom.12281. Epub 2015 Jan 13. Biometrics. 2015. PMID: 25585942 Free PMC article.
-
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials.BMJ Open. 2013 Mar 13;3(3):e001802. doi: 10.1136/bmjopen-2012-001802. BMJ Open. 2013. PMID: 23485717 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources